Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.
| Revenue (TTM) | $243.12M |
| Gross Profit (TTM) | $40.61M |
| EBITDA | $-55.34M |
| Operating Margin | 0.00% |
| Return on Equity | -9.27% |
| Return on Assets | -5.78% |
| Revenue/Share (TTM) | $4.83 |
| Book Value | $7.59 |
| Price-to-Book | 0.61 |
| Price-to-Sales (TTM) | 0.64 |
| EV/Revenue | 1.401 |
| EV/EBITDA | 5.29 |
| Quarterly Earnings Growth (YoY) | -84.70% |
| Quarterly Revenue Growth (YoY) | 23.90% |
| Shares Outstanding | $15.00M |
| Float | $7.86M |
| % Insiders | 39.17% |
| % Institutions | 1.05% |
Volatility is currently expanding
Company intends to accelerate the rehabilitation of Canndoc's flagship Nir Oz facility, supporting a return to full production and the Company's expansion in the growing German medical cannabis market
NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company's prior reports regarding growing demand in Germany and opportunities arising from the recent U.S. federal rescheduling of cannabis, the Company has entered into a binding term sheet providing for funding commitments of NIS 22 million (approximately US$7.4 million), which may increase to NIS 54 million (approximately US$18.6 million) (the “Private Placement”).
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INCR and any ticker you trade — then tracks every position and per-strategy win rate.
